Inhibikase Therapeutics Inc
NASDAQ:IKT
Inhibikase Therapeutics Inc
Inhibikase Therapeutics, Inc. provides infectious disease treatments. The company is headquartered in Atlanta, Georgia and currently employs 6 full-time employees. The company went IPO on 2020-12-23. The firm is focused on developing therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The firm's product candidates include IkT-148009, IkT-001pro, and IKT-01427. Its lead product candidate, IkT-148009 is for the treatment of PD and for the treatment of gastrointestinal (GI), complications that arise as early symptoms of PD in patients. The Company’s kT-148009 is a brain penetrant c-Abl protein kinase inhibitor that halts disease progression and reverses functional loss in the brain and reverses neurological dysfunction in the GI tract. Its product candidate IkT-001Pro, is a prodrug of the anticancer agent Imatinibm, and used as a treatment for chronic myelogenous leukemia (CML). IkT-01427 is an oral, brain-penetrant medication , designed to block the entry of the JC virus into the cell, thereby preventing the virus’ ability to replicate in the body.
Inhibikase Therapeutics, Inc. provides infectious disease treatments. The company is headquartered in Atlanta, Georgia and currently employs 6 full-time employees. The company went IPO on 2020-12-23. The firm is focused on developing therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The firm's product candidates include IkT-148009, IkT-001pro, and IKT-01427. Its lead product candidate, IkT-148009 is for the treatment of PD and for the treatment of gastrointestinal (GI), complications that arise as early symptoms of PD in patients. The Company’s kT-148009 is a brain penetrant c-Abl protein kinase inhibitor that halts disease progression and reverses functional loss in the brain and reverses neurological dysfunction in the GI tract. Its product candidate IkT-001Pro, is a prodrug of the anticancer agent Imatinibm, and used as a treatment for chronic myelogenous leukemia (CML). IkT-01427 is an oral, brain-penetrant medication , designed to block the entry of the JC virus into the cell, thereby preventing the virus’ ability to replicate in the body.
Clinical Progress: Inhibikase completed enrollment in its Phase II 201 Trial of risvodetinib for untreated Parkinson's disease, with top-line data expected in November 2024.
Pipeline Expansion: The company filed an IND for IkT-001Pro in pulmonary arterial hypertension (PAH), aiming to start a Phase IIb trial later this year.
Financial Position: Inhibikase raised $4 million in May, extending its cash runway into December 2024, which will fund operations through key upcoming milestones.
Cost Management: Net loss and R&D expenses decreased year-over-year, primarily due to the completion of a major study for IkT-001Pro.
Upcoming Milestones: The company anticipates starting an open-label extension study for risvodetinib and expects potential catalysts in both its Parkinson's and PAH programs later in the year.
